최승재

All filings by 최승재 on record concern 셀트리온제약, in the capacity of senior executive. We count 4 filings; the first trade dates from 31 January 2023 and the latest from 24 March 2026.

Purchases make up the whole of the open-market record (4 purchases, €9,909). The amount is not disclosed for 1 filing. Unlike grants, an open-market purchase is paid for by the insider, at the market price. In 2026 alone, the filings show 1 purchase and no sales.

The median purchase comes to €82. On 2 out of 3 purchases, another insider of the same company was buying within the same 30 days. A cluster is several different insiders buying the same stock within a short window, a pattern studied more closely than a single purchase.

The latest filing, published on 3 April 2026, reports an open-market purchase of €30 in 셀트리온제약. Filings reach the DART (FSS) feed a median of 10 days after the trade. That lag is the time during which only the insider knows about the trade. This summary is built from DART (FSS) disclosures alone and does not predict where the share price will go.